Newspaper Advertisement of Financial Results under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Transgene Biotek has submitted newspaper clippings of its audited financial results for the quarter and full year ended March 31, 2026, published in Business Standard (English) and Navatelangana (Telugu), as required under SEBI Regulation 47. The Board of Directors approved the results at their meeting held on May 29, 2026. Total income from operations stood at Rs 20.43 lakh in Q4 FY26 (vs Rs 12.03 lakh in Q4 FY25) and Rs 36.11 lakh for the full year (flat versus FY25). The company reported a net loss of Rs 45.70 lakh in Q4 FY26, narrower than the Rs 71.31 lakh loss in Q4 FY25, while the full-year FY26 net loss remained unchanged at Rs 165.29 lakh. EPS stood at Rs -0.06 for Q4 and Rs -0.22 for the full year. Results include consolidated figures of the subsidiary.
The company continues to post losses with no improvement in full-year profitability, though the quarterly loss narrowed compared to a year ago. Flat annual revenue and persistent losses are negative signals for shareholders, suggesting limited operating momentum in the near term.